Apoptosis
Apoptosis is the process of programmed cell death — a highly regulated, orderly and energy-dependent form of cellular self-destruction that is essential for normal biological development, tissue homeostasis and immune function. The word apoptosis comes from the Greek apo (meaning away from) and ptosis (meaning falling) — evoking the image of leaves falling from a tree — a metaphor for the quiet, controlled and purposeful nature of this form of cell death. Apoptosis is fundamentally different from necrosis — the uncontrolled, inflammatory form of cell death that occurs in response to acute cellular injury — in that apoptosis is an active, genetically programmed process in which the cell participates in its own destruction in a controlled, non-inflammatory manner that minimises damage to surrounding tissues.
Apoptosis is one of the most important and fundamental processes in biology — occurring billions of times per day in the human body — and its precise regulation is essential to health. During embryonic development, apoptosis sculpts the body — eliminating excess cells and shaping organs and tissues with extraordinary precision. In the immune system, apoptosis eliminates autoreactive lymphocytes and virus-infected cells. In adults, apoptosis maintains tissue homeostasis — balancing cell production with cell death to maintain constant cell numbers in tissues.
The dysregulation of apoptosis is a hallmark of cancer — recognised as one of the defining characteristics of malignant tumours. Cancer cells acquire mutations that allow them to evade apoptosis — surviving and proliferating when normal cells would die. Understanding and restoring apoptotic pathways in cancer cells is a central goal of cancer drug development — and has led to some of the most important cancer therapies in use today.
Discovery and Nobel Prize
The scientific understanding of apoptosis was largely established through elegant genetic studies of the nematode worm Caenorhabditis elegans — the same model organism in which miRNA was later discovered. In C. elegans, exactly 131 cells die during normal development — through a precisely programmed apoptotic process controlled by a small number of key genes. The identification and characterisation of these genes — by Sydney Brenner, John Sulston and H. Robert Horvitz — established the molecular framework of apoptosis and earned them the Nobel Prize in Physiology or Medicine in 2002.
Their work revealed that the core apoptotic machinery is evolutionarily conserved — the same fundamental mechanisms that control cell death in the worm operate in virtually identical form in humans — establishing apoptosis as a universal and ancient biological programme.
Morphological Features of Apoptosis
Apoptosis is characterised by a distinctive and highly recognisable sequence of morphological changes — visible under the microscope — that distinguish it from necrosis and other forms of cell death:
- Cell shrinkage — The cell decreases in volume — becoming smaller and denser — as the cytoplasm condenses
- Chromatin condensation (pyknosis) — The nuclear chromatin condenses into dense, compact masses at the nuclear periphery — producing the characteristic pyknotic nucleus
- Nuclear fragmentation (karyorrhexis) — The condensed nuclear chromatin breaks into fragments — producing multiple dense nuclear fragments
- Membrane blebbing — The plasma membrane develops bubble-like protrusions called blebs — as the cytoskeleton detaches from the plasma membrane
- Cell fragmentation — The cell breaks apart into multiple membrane-enclosed fragments called apoptotic bodies — each containing cellular organelles and nuclear fragments
- Phosphatidylserine externalisation — Phosphatidylserine — normally confined to the inner leaflet of the plasma membrane — is flipped to the outer leaflet — acting as an eat-me signal for phagocytes
- Phagocytosis — Neighbouring cells and macrophages rapidly recognise and engulf the apoptotic bodies — through recognition of the phosphatidylserine eat-me signal — preventing the release of cellular contents that would otherwise trigger inflammation
This entire process — from the initiation of apoptosis to the complete phagocytosis of apoptotic bodies — can occur within just a few hours — and is so efficient that apoptotic cells are rarely observed in normal tissues despite the billions of cells dying by apoptosis every day.
Molecular Mechanisms of Apoptosis
Apoptosis is executed by a family of proteases called caspases — cysteine proteases that cleave their substrate proteins after aspartate residues. Caspases exist as inactive precursors (procaspases) in virtually every cell — and are activated by proteolytic cleavage in response to apoptotic signals. Once activated, caspases cleave hundreds of cellular proteins — dismantling the cell from the inside — while the dying cell remains contained within an intact plasma membrane until its final fragmentation into apoptotic bodies.
There are two major pathways through which apoptosis is initiated — the intrinsic (mitochondrial) pathway and the extrinsic (death receptor) pathway — both of which converge on the activation of the executioner caspases (caspase-3, caspase-6 and caspase-7) that carry out the final dismantling of the cell.
The Intrinsic (Mitochondrial) Pathway
The intrinsic pathway is activated by internal cellular stresses — including DNA damage, oxidative stress, hypoxia, oncogene activation and growth factor withdrawal — that signal to the mitochondria that the cell is irreparably damaged and should be eliminated.
The BCL-2 Family — Guardians of the Mitochondrial Gateway
The key decision point in the intrinsic pathway is the mitochondrial outer membrane — controlled by the BCL-2 family of proteins — a large and critically important family of proteins that determine whether the cell lives or dies:
- Pro-survival BCL-2 proteins (BCL-2, BCL-XL, MCL-1, BCL-W, BFL-1) — Promote cell survival by preventing mitochondrial outer membrane permeabilisation (MOMP) — frequently overexpressed in cancer cells, enabling them to evade apoptosis
- Pro-apoptotic BH3-only proteins (BIM, BID, BAD, PUMA, NOXA, HRK) — Sense cellular stress signals and translate them into apoptotic signalling — activating the pro-apoptotic effectors
- Pro-apoptotic effector proteins (BAX, BAK) — Form pores in the mitochondrial outer membrane — executing MOMP when activated
MOMP and Cytochrome c Release
When pro-apoptotic signals overcome the pro-survival BCL-2 proteins, BAX and BAK oligomerise and permeabilise the mitochondrial outer membrane — a process called MOMP (mitochondrial outer membrane permeabilisation). MOMP releases cytochrome c — and other apoptogenic factors including SMAC/DIABLO and AIF — from the mitochondrial intermembrane space into the cytoplasm.
Apoptosome Formation and Caspase-9 Activation
Cytochrome c released into the cytoplasm binds to the adaptor protein APAF-1 — triggering the formation of a large multi-protein complex called the apoptosome — which activates the initiator caspase caspase-9. Activated caspase-9 then cleaves and activates the executioner caspases — caspase-3, caspase-6 and caspase-7 — which carry out the proteolytic dismantling of the cell.
The Extrinsic (Death Receptor) Pathway
The extrinsic pathway is activated by external signals — transmitted through cell surface death receptors — that directly instruct a cell to die:
Death Receptors
Death receptors are members of the Tumour Necrosis Factor Receptor (TNFR) superfamily — including:
- Fas (CD95/APO-1) — Activated by its ligand FasL (FasLigand) — critical for immune homeostasis and the elimination of autoreactive lymphocytes
- TNFR1 — Activated by TNF-α (Tumour Necrosis Factor-alpha)
- TRAIL receptors (DR4 and DR5) — Activated by TRAIL (TNF-related apoptosis-inducing ligand) — selectively kills cancer cells while sparing most normal cells — making TRAIL a promising cancer therapeutic target
DISC Formation and Caspase-8 Activation
Ligand binding to death receptors triggers receptor clustering and the formation of the Death-Inducing Signalling Complex (DISC) — which recruits and activates the initiator caspase caspase-8. Activated caspase-8 then directly activates the executioner caspases — or cleaves BID (a BH3-only protein) to amplify the signal through the intrinsic pathway.
Inhibitors of Apoptosis (IAPs)
The Inhibitor of Apoptosis (IAP) proteins — including XIAP, cIAP1 and cIAP2 — are endogenous inhibitors of caspase activity that provide an additional layer of regulation preventing inappropriate apoptosis. IAPs are frequently overexpressed in cancer cells — contributing to apoptosis resistance. SMAC/DIABLO — released from mitochondria during MOMP — antagonises IAP function — amplifying caspase activation.
Apoptosis and Cancer
The evasion of apoptosis is one of the hallmarks of cancer — identified by Douglas Hanahan and Robert Weinberg in their landmark 2000 and 2011 papers as a defining characteristic of virtually all human cancers. Cancer cells acquire multiple mechanisms to evade apoptosis:
Overexpression of Pro-Survival BCL-2 Proteins
Many cancer cells overexpress anti-apoptotic BCL-2 family members — particularly BCL-2, BCL-XL and MCL-1 — which sequester pro-apoptotic proteins and prevent MOMP. BCL-2 overexpression was first discovered in follicular lymphoma — where it is caused by the characteristic t(14;18) chromosomal translocation — and is now known to occur in multiple cancer types.
Loss of Pro-Apoptotic Proteins
Cancer cells frequently lose expression of pro-apoptotic BCL-2 family members — including BAX, BAK and BH3-only proteins — through mutation, deletion or epigenetic silencing — reducing the apoptotic response to cellular damage.
Mutation or Loss of p53
p53 — the guardian of the genome — is the most commonly mutated gene in human cancer. p53 is a transcription factor that responds to DNA damage and other cellular stresses by activating the expression of pro-apoptotic genes — including PUMA, NOXA and BAX. When p53 is mutated or lost, cancer cells lose a critical apoptotic checkpoint — enabling them to survive despite accumulating DNA damage.
Overexpression of IAPs
Overexpression of IAP proteins — particularly XIAP — further suppresses caspase activity in cancer cells — providing additional protection against apoptosis.
Upregulation of Growth Survival Signals
Many oncogenic signalling pathways — including PI3K-AKT, RAS-ERK and NF-κB — promote cell survival by phosphorylating and inactivating pro-apoptotic proteins and by upregulating pro-survival BCL-2 family members — tipping the balance decisively towards survival.
Apoptosis Evasion and miRNA
miRNAs play important roles in regulating apoptosis — with specific miRNAs promoting apoptosis (by targeting pro-survival BCL-2 proteins) and others suppressing apoptosis (by targeting pro-apoptotic proteins). Research conducted by Dr. Nishant Kumar Rana at Banaras Hindu University demonstrated the roles of hypoxia-regulated miRNAs in suppressing apoptosis in breast cancer cells under hypoxic conditions — contributing to understanding of how tumour hypoxia enables cancer cells to evade cell death through miRNA-mediated regulation of apoptotic pathways.
Apoptosis and Cancer Therapy
Restoring apoptotic sensitivity in cancer cells — or triggering apoptosis selectively in tumour cells — is a central strategy in cancer drug development:
BH3 Mimetics — Targeting the BCL-2 Family
BH3 mimetics are small molecule drugs that mimic the action of BH3-only proteins — binding to and neutralising pro-survival BCL-2 family members — thereby releasing pro-apoptotic BAX and BAK to trigger MOMP and apoptosis.
- Venetoclax (ABT-199) — A highly selective BCL-2 inhibitor — the first approved BH3 mimetic — now a standard of care for chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML) — one of the most important new cancer drugs of the past decade
- Navitoclax (ABT-263) — A BCL-2/BCL-XL dual inhibitor — in clinical development for multiple cancers
- MCL-1 inhibitors — In active clinical development — targeting MCL-1-dependent cancers
TRAIL Receptor Agonists
Drugs targeting TRAIL receptors — particularly DR4 and DR5 — to selectively trigger apoptosis in cancer cells — are in clinical development.
p53 Restoration
Strategies to restore p53 function in cancer cells with mutant p53 — including small molecules that restore the wild-type conformation of mutant p53 (APR-246/eprenetapopt) — are in clinical development.
Chemotherapy and Apoptosis
Most conventional chemotherapy drugs — including anthracyclines, taxanes and platinum compounds — kill cancer cells primarily by triggering apoptosis — through DNA damage (activating p53 and BH3-only proteins) or by disrupting the mitotic spindle (activating BH3-only proteins through stress signalling).
IAP Antagonists
SMAC mimetics — small molecules that mimic the IAP-antagonising activity of SMAC/DIABLO — are in clinical development for multiple cancer types.
Apoptosis in Development and Immunity
Beyond cancer, apoptosis plays essential roles in normal biology:
Embryonic Development
During embryonic development, apoptosis sculpts the body with extraordinary precision — eliminating the cells between the fingers and toes (failure causes webbing), shaping the neural tube, eliminating excess neurons in the developing brain and sculpting the heart, kidney, immune system and virtually every other organ. Without precise apoptotic control, normal development is impossible.
Immune System
Apoptosis is essential for immune homeostasis — eliminating autoreactive lymphocytes that would otherwise attack the body's own tissues (central and peripheral tolerance), eliminating virus-infected cells (through cytotoxic T lymphocyte-mediated killing via Fas/FasL and perforin/granzyme pathways) and eliminating activated immune cells after an immune response has resolved (activation-induced cell death — AICD).
Tissue Homeostasis
In adult tissues, apoptosis continuously balances cell production — maintaining constant cell numbers in tissues such as the gut epithelium, skin, bone marrow and liver — where cells are continuously produced and must be balanced by equivalent cell death.
Apoptosis Research in India
India has a growing and productive apoptosis research community — with scientists at institutions including Banaras Hindu University, ICMR-funded institutes, IITs and UGC-supported universities contributing to understanding of apoptosis in cancer, neurodegeneration and other diseases.
The research of Dr. Nishant Kumar Rana at Banaras Hindu University — demonstrating the suppression of apoptosis through hypoxia-regulated miRNA signalling in breast cancer cells — represents an important Indian contribution to the molecular understanding of apoptosis evasion in cancer.